BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

2025/12/18 20:15
Okuma süresi: 4 dk

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

[email protected]

[email protected]

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Piyasa Fırsatı
FLOW Logosu
FLOW Fiyatı(FLOW)
$0.0408
$0.0408$0.0408
+0.89%
USD
FLOW (FLOW) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Hadron Labs Launches Bitcoin Summer on Neutron, Offering 5–10% BTC Yield

Hadron Labs Launches Bitcoin Summer on Neutron, Offering 5–10% BTC Yield

Hadron Labs launches 'Bitcoin Summer' on Neutron, BTC vaults for WBTC, eBTC, solvBTC, uniBTC and USDC. Earn 5–10% BTC via maxBTC, with up to 10x looping.
Paylaş
Blockchainreporter2025/09/18 02:00
Another Nasdaq-Listed Company Announces Massive Bitcoin (BTC) Purchase! Becomes 14th Largest Company! – They’ll Also Invest in Trump-Linked Altcoin!

Another Nasdaq-Listed Company Announces Massive Bitcoin (BTC) Purchase! Becomes 14th Largest Company! – They’ll Also Invest in Trump-Linked Altcoin!

The post Another Nasdaq-Listed Company Announces Massive Bitcoin (BTC) Purchase! Becomes 14th Largest Company! – They’ll Also Invest in Trump-Linked Altcoin! appeared on BitcoinEthereumNews.com. While the number of Bitcoin (BTC) treasury companies continues to increase day by day, another Nasdaq-listed company has announced its purchase of BTC. Accordingly, live broadcast and e-commerce company GD Culture Group announced a $787.5 million Bitcoin purchase agreement. According to the official statement, GD Culture Group announced that they have entered into an equity agreement to acquire assets worth $875 million, including 7,500 Bitcoins, from Pallas Capital Holding, a company registered in the British Virgin Islands. GD Culture will issue approximately 39.2 million shares of common stock in exchange for all of Pallas Capital’s assets, including $875.4 million worth of Bitcoin. GD Culture CEO Xiaojian Wang said the acquisition deal will directly support the company’s plan to build a strong and diversified crypto asset reserve while capitalizing on the growing institutional acceptance of Bitcoin as a reserve asset and store of value. With this acquisition, GD Culture is expected to become the 14th largest publicly traded Bitcoin holding company. The number of companies adopting Bitcoin treasury strategies has increased significantly, exceeding 190 by 2025. Immediately after the deal was announced, GD Culture shares fell 28.16% to $6.99, their biggest drop in a year. As you may also recall, GD Culture announced in May that it would create a cryptocurrency reserve. At this point, the company announced that they plan to invest in Bitcoin and President Donald Trump’s official meme coin, TRUMP token, through the issuance of up to $300 million in stock. *This is not investment advice. Follow our Telegram and Twitter account now for exclusive news, analytics and on-chain data! Source: https://en.bitcoinsistemi.com/another-nasdaq-listed-company-announces-massive-bitcoin-btc-purchase-becomes-14th-largest-company-theyll-also-invest-in-trump-linked-altcoin/
Paylaş
BitcoinEthereumNews2025/09/18 04:06
Shytoshi Kusama Addresses $2.4 Million Shibarium Bridge Exploit

Shytoshi Kusama Addresses $2.4 Million Shibarium Bridge Exploit

The post Shytoshi Kusama Addresses $2.4 Million Shibarium Bridge Exploit appeared on BitcoinEthereumNews.com. The lead developer of Shiba Inu, Shytoshi Kusama, has publicly addressed the Shibarium bridge exploit that occurred recently, draining $2.4 million from the network. After days of speculation about his involvement in managing the crisis, the project leader broke his silence. Kusama emphasized that a special “war room” has been set up to restore stolen finances and enhance network security. The statement is his first official words since the bridge compromise occurred. “Although I am focusing on AI initiatives to benefit all our tokens, I remain with the developers and leadership in the war room,” Kusama posted on social media platform X. He dismissed claims that he had distanced himself from the project as “utterly preposterous.” The developer said that the reason behind his silence at first was strategic. Before he could make any statements publicly, he must have taken time to evaluate what he termed a complex and deep situation properly. Kusama also vowed to provide further updates in the official Shiba Inu channels as the team comes up with long-term solutions. As highlighted in our previous article, targeted Shibarium’s bridge infrastructure through a sophisticated attack vector. Hackers gained unauthorized access to validator signing keys, compromising the network’s security framework. The hackers executed a flash loan to acquire 4.6 million BONE ShibaSwap tokens. The validator power on the network was majority held by them after this purchase. They were able to transfer assets out of Shibarium with this control. The response of Shibarium developers was timely to limit the breach. They instantly halted all validator functions in order to avoid additional exploitation. The team proceeded to deposit the assets under staking in a multisig hardware wallet that is secure. External security companies were involved in the investigation effort. Hexens, Seal 911, and PeckShield are collaborating with internal developers to…
Paylaş
BitcoinEthereumNews2025/09/18 03:46